Does LISOCABTAGENE MARALEUCEL Cause Malignant neoplasm progression? 23 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 23 reports of Malignant neoplasm progression have been filed in association with LISOCABTAGENE MARALEUCEL (BREYANZI). This represents 3.1% of all adverse event reports for LISOCABTAGENE MARALEUCEL.
23
Reports of Malignant neoplasm progression with LISOCABTAGENE MARALEUCEL
3.1%
of all LISOCABTAGENE MARALEUCEL reports
13
Deaths
10
Hospitalizations
How Dangerous Is Malignant neoplasm progression From LISOCABTAGENE MARALEUCEL?
Of the 23 reports, 13 (56.5%) resulted in death, 10 (43.5%) required hospitalization, and 4 (17.4%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for LISOCABTAGENE MARALEUCEL. However, 23 reports have been filed with the FAERS database.
What Other Side Effects Does LISOCABTAGENE MARALEUCEL Cause?
Cytokine release syndrome (315)
Immune effector cell-associated neurotoxicity syndrome (129)
Neurotoxicity (101)
Pyrexia (47)
Fatigue (38)
Hypotension (38)
Febrile neutropenia (28)
Confusional state (27)
Death (25)
Lymphocyte adoptive therapy (25)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which LISOCABTAGENE MARALEUCEL Alternatives Have Lower Malignant neoplasm progression Risk?
LISOCABTAGENE MARALEUCEL vs LITHIUM
LISOCABTAGENE MARALEUCEL vs LIXISENATIDE
LISOCABTAGENE MARALEUCEL vs LOBAPLATIN
LISOCABTAGENE MARALEUCEL vs LOFEXIDINE
LISOCABTAGENE MARALEUCEL vs LOMITAPIDE